Literature DB >> 9406055

Application of immunomagnetic beads in combination with RT-PCR for the detection of circulating prostate cancer cells.

A N Makarovskiy1, W Ackerley, L Wojcik, G K Halpert, B S Stein, M P Carreiro, D C Hixson.   

Abstract

Recently published protocols using Reverse Transcriptase Polymerase Chain reaction (RT-PCR) for prostate specific antigen (PSA) provide a sensitive means for detecting circulating prostate cancer cells. Attempts to use these assays for staging of prostate cancer have produced conflicting results. As a first step towards rectifying these discrepancies, a modified immunobead-RT-PCR assay capable of detecting as few as 10 prostate cancer cells in 8cc of blood was developed. This 10 fold increase in sensitivity was achieved in part by introducing two target cell enrichment steps. As a model system to assess sensitivity of the modified assay, template RNA was extracted from PSA positive human carcinoma cells suspended in human blood and isolated with immunomagnetic beads following incubation with an epithelium specific antibody. After 45 cycles of PCR, product from as few as 10 target cells could be readily detected when displayed on a 2% agarose gel stained with SYBR Green fluorescent dye. The identity of amplified DNA fragments was confirmed by Southern blot hybridization. When applied to blood samples from patients with proven metastatic disease, the immuno-bead RT-PCR assay was successful in detecting circulating PSA positive epithelial cells, suggesting this assay may be useful for assessment of disease progression or recurrence.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9406055      PMCID: PMC6760733          DOI: 10.1002/(sici)1098-2825(1997)11:6<346::aid-jcla7>3.0.co;2-3

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  9 in total

1.  Immunobead-PCR: a technique for the detection of circulating tumor cells using immunomagnetic beads and the polymerase chain reaction.

Authors:  J E Hardingham; D Kotasek; B Farmer; R N Butler; J X Mi; R E Sage; A Dobrovic
Journal:  Cancer Res       Date:  1993-08-01       Impact factor: 12.701

2.  Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial.

Authors:  U Latza; G Niedobitek; R Schwarting; H Nekarda; H Stein
Journal:  J Clin Pathol       Date:  1990-03       Impact factor: 3.411

3.  Association of pp60c-src with biliary glycoprotein (CD66a), an adhesion molecule of the carcinoembryonic antigen family downregulated in colorectal carcinomas.

Authors:  J Brümmer; M Neumaier; C Göpfert; C Wagener
Journal:  Oncogene       Date:  1995-10-19       Impact factor: 9.867

4.  Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases.

Authors:  M R Smith; S Biggar; M Hussain
Journal:  Cancer Res       Date:  1995-06-15       Impact factor: 12.701

5.  Detection of hematogenous micrometastasis in patients with prostate cancer.

Authors:  J G Moreno; C M Croce; R Fischer; M Monne; P Vihko; S G Mulholland; L G Gomella
Journal:  Cancer Res       Date:  1992-11-01       Impact factor: 12.701

6.  [Detection of estrogen receptor (ER) mRNA by use of reverse transcriptase-polymerase chain reaction (RT-PCR) assay; comparison with dextran coated charcoal (DCC) assay and immunocytochemical assay].

Authors:  T Ozaki
Journal:  Gan To Kagaku Ryoho       Date:  1992-03

7.  Detection of liver cells in peripheral blood of patients with advanced-stage hepatocellular carcinoma.

Authors:  S Kar; B I Carr
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

8.  Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay.

Authors:  A E Katz; C A Olsson; A J Raffo; C Cama; H Perlman; E Seaman; K M O'Toole; D McMahon; M C Benson; R Buttyan
Journal:  Urology       Date:  1994-06       Impact factor: 2.649

9.  Detection of circulating tumor cells in men with localized prostate cancer.

Authors:  M V Seiden; P W Kantoff; K Krithivas; K Propert; M Bryant; E Haltom; L Gaynes; I Kaplan; G Bubley; W DeWolf
Journal:  J Clin Oncol       Date:  1994-12       Impact factor: 44.544

  9 in total
  7 in total

Review 1.  Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes.

Authors:  Lori M Millner; Mark W Linder; Roland Valdes
Journal:  Ann Clin Lab Sci       Date:  2013       Impact factor: 1.256

2.  Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven.

Authors:  A L Woynarowska BAHigdon; R M Muñoz; P Bushong; S J Waters
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

Review 3.  Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads.

Authors:  Lisa Y Wu; Tiancheng Liu; Mark R Hopkins; William C Davis; Clifford E Berkman
Journal:  Prostate       Date:  2012-04-04       Impact factor: 4.104

Review 4.  Detection and isolation of circulating tumor cells in urologic cancers: a review.

Authors:  Robert D Loberg; Yaron Fridman; Brian A Pienta; Evan T Keller; Laurie K McCauley; Russell S Taichman; Kenneth J Pienta
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

Review 5.  Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance.

Authors:  Zacharoula Panteleakou; Peter Lembessis; Antigone Sourla; Nikolaos Pissimissis; Aristides Polyzos; Charalambos Deliveliotis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008-12-03       Impact factor: 6.354

6.  Optimization of the reverse transcriptase polymerase chain reaction for the detection of circulating prostate cells.

Authors:  I G McIntyre; K Spreckley; R B Clarke; E Anderson; N W Clarke; N J George
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

Review 7.  Dissecting the Heterogeneity of Circulating Tumor Cells in Metastatic Breast Cancer: Going Far Beyond the Needle in the Haystack.

Authors:  Michela Bulfoni; Matteo Turetta; Fabio Del Ben; Carla Di Loreto; Antonio Paolo Beltrami; Daniela Cesselli
Journal:  Int J Mol Sci       Date:  2016-10-24       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.